Erratum (DOI:10.1016/j.explore.2005.12.003);Reporting random controlled trials of herbal medicines

Explore: The Journal of Science and Healing

Volumn 2, Issue 2, 2006, Pages 143-149

  Gagnier, Joel ^a,j   Boon, Heather ^a   Rochon, Paula ^a,b,f,g   Barnes, Joanne ^c   Moher, David ^d,h   Bombardier, Claire ^a,e,i  

^a UNIVERSITY OF TORONTO   (Canada)

^b BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^e INSTITUTE FOR WORK AND HEALTH   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^g Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j Toronto General Research Institute ^*  (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT;

ABSTRACT REPORT; ARTICLE; CANADA; CLINICAL STUDY; CLINICAL TRIAL; CONSENSUS; DATA ANALYSIS; DRUG MANUFACTURE; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; MEDICAL EXPERT; METHODOLOGY; OUTCOME ASSESSMENT; PHARMACOGNOSY; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICS; TELEPHONE; UNSPECIFIED SIDE EFFECT;

EID: 33644932170     PISSN: 15508307     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.explore.2006.05.023     Document Type: Erratum

References (34)

1. D.G. Altman K.F. Schulz D. Moher CONSORT Group The revised consort statement for reporting randomized trials: Explanation and elaboration Ann Intern Med. 134 2001 663-694
2. K.F. Schulz I. Chalmers R.J. Hayes D.G. Altman Empirical evidence of bias dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 273 1995 408-412
3. C.B. Begg M.K. Cho S. Eastwood et. al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement JAMA 76 1996 637-639
4. CONSORT Group (Consolidated Standards of Reporting Trials) D. Moher K.F. Schulz D. Altman The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials JAMA 285 2001 1987-1991
5. CONSORT Group D. Moher D.G. Altman K.F. Schulz D.R. Elbourne Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond Can Med Assoc J. 171 2004 349-350
6. CONSORT Group M.K. Campbell D.R. Elbourne D.G. Altman CONSORT: Statement extension to cluster randomized trials BMJ 328 2004 702-708
7. J.P.A. Ioannidis S. Evans P.C. Goslashzsche et. al. D. Moher CONSORT Group Better reporting of arms in randomized: Trials an extension of the CONSORT Statement Ann Intern Med. 141 2004 781-788
8. C. Little T. Parsons Herbal therapy for treating rheumatoid arthritis Cochrane Library 2000 4
9. K. Linde W.B. Jonas D. Melchart S. Willich The methodological quality of randomized controlled trials of homeopathy, herbal medicines and acupuncture Int J Epidemiol. 30 2001 526-531
10. D. Moher M. Sampson K. Campbell et. al. Assessing the quality of reports of randomized trials in pediatric and complementary and alternative medicine BMC Pediatr. 2 2002
11. Gagnier JJ, DeMelo J, Boon H, Rochon P, Bombardier C. Quality of reports of randomized controlled intervention trials of botanical medicines (in press).
12. T.P. Klassen B. Pham M.L. Lawson D. Moher The quality of reports of complementary and alternative medicine randomized controlled trials is as good as conventional medicine reports of randomized controlled trials J Clin Epidemiol. 58 8 2005 763
13. K. Huwiler-Muntener P. Juni C. Junker M. Egger Quality of reporting of randomized trials as a measure of methodologic quality JAMA 287 2002 2801-2804
14. D. Moher A. Jones L. Lepage CONSORT Group Use of the CONSORT statement and quality of reports of randomized trials: A comparative before and after evaluation JAMA 285 2001 1992-1995
15. M.R. Harkey G.L. Henderson M.E. Gershwin J.S. Stern R.M. Hackman Variability in commercial Ginseng products an analysis of 25 preparations Am J Clin Nutr 75 2002 600-601
16. W.A. Groenewegen S. Heptinstall Amounts of feverfew in commercial preparations of the herb Lancet 1 1986 44-45
17. S. Heptinstall D.V. Awang B.A. Dawson et. al. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium [L.] Schultz-Bip.). Estimation of commercial and authenticated feverfew products J Pharm Pharmacol. 44 1992 391-395
18. M.H. Nelson S.E. Cobb J. Shelton Variations in parthenolide content and daily dose of feverfew products Am J Health Syst Pharm. 59 2002 1527-1531
19. J. Manning J.C. Roberts Analysis of catechin content of commercial green tea products J Herb Pharmacother. 3 2003 19-32
20. M. Carlson R.D. Thompson Liquid chromatographic determination of methylxanthines and catechins in herbal preparations containing guarana J AOAC Int. 81 1998 691-701
21. C.A. Haller M. Duan N.L. Benowitz P. Jacob Concentrations of Ephedra alkaloids and caffeine in commercial dietary supplements J Anal Toxicol. 28 2004 145-151
22. S. Kressmann W.E. Muller H.H. Blume Pharmaceutical quality of different Ginkgo biloba brands J Pharm Pharmacol. 54 2002 661-669
23. B.J. Gurley S.F. Gardner M.A. Hubbard Content versus label claims in ephedra-containing dietary supplements Am J Health Syst Pharm. 57 2000 963-969
24. G.C. De Los Reyes R.T. Koda Determining hyperforin and hypericin content in eight brands of St. John's wort Am J Health Syst Pharm. 59 2002 545-547
25. S. Schulte-Lobbert G. Holloubek W.E. Muller M. Schubert-Zsilavecz M. Wurglics Comparison of the synapotosomal uptake inhibition of serotonin by St. John's wort products J Pharm Pharmacol. 56 2004 813-818
26. S. Kressmann A. Biber M. Wonnemann B. Schug H.H. Blume W.E. Muller Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations J Pharm Pharmacol. 54 2002 1507-1514
27. N.H. Oberlies N.C. Kim D.R. Brine et. al. Analysis of herbal teas made from the leaves of comfrey (Symphytum officinale) reduction of N-Oxides results in order of magnitude increases in the measurable concentration of pyrrolizidine alkaloids Public Health Nutr. 7 2004 919-924
28. J. Barnes Pharmacovigilance of herbal medicines. A UK perspective Drug Saf. 26 2003 829-851
29. K. Linde S.N. Willich How objective are systematic reviews? Differences between reviews on complementary medicine J Royal Soc. Med. 96 2003 17-22
30. A. Bowling Research Methods in Health 2nd ed. 2002 Open University Press Maidenhead, UK
31. P.J. Devereaux B.J. Manns W.A. Ghali H. Quan G.H. Guyatt The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist Contr Clin Trials 23 2002 380-388
32. J.J. Gagnier H. Boon P. Rochon J Barnes D. Moher C.B. Bombardier CONSORT Group Reporting randomized controlled trials of herbal interventions an elaborated CONSORT statement Ann Intern Med. 2006 March (In Press)
33. D.L. Streiner G.L. Norman Health Measurement Scales A Practical Guide to Their Use and Development 2001 Oxford Medical Publication Oxford
34. J.J. Gagnier H. Boon P. Rochon J. Barnes D. Moher C.B. Bombardier CONSORT Group CONSORT extension to randomized controlled trials of herbal medicinal products. explanation and implementation J Clin Epidemiol. 2006 March (In Press)